| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
IBRX
ImmunityBio
|
Feb 02, 2026 | BUY |
Strong Buy
+52.6% avg upside
12 analysts
|
$9.00
22.26% Upside
|
+30.0% |
|
JANX
Janux Therapeutics Inc
|
Jan 22, 2026 | BUY |
Strong Buy
+217.1% avg upside
21 analysts
|
$100.00
603.22% Upside
|
-6.5% |
|
NBP
NovaBridge Biosciences
|
Jan 06, 2026 | BUY |
Strong Buy
+1309.7% avg upside
14 analysts
|
$9.00
499.95% Upside
|
· |
|
AVBP
ArriVent BioPharma, Inc.
|
Jan 02, 2026 | BUY |
Strong Buy
+37.0% avg upside
15 analysts
|
$45.00
41.82% Upside
|
+50.8% |
|
SNDX
Syndax Pharmaceuticals
|
Jan 02, 2026 | BUY |
Strong Buy
+88.8% avg upside
27 analysts
|
$56.00
194.68% Upside
|
-14.0% |
|
KURA
Kura Oncology
|
Dec 09, 2025 | HOLD |
Strong Buy
+161.3% avg upside
26 analysts
|
— | -10.3% |
|
TCRX
TScan Therapeutics
|
Dec 09, 2025 | HOLD |
Strong Buy
+823.9% avg upside
12 analysts
|
— | -11.3% |
|
AAPG
Ascentage Pharma Group International Unsponsored ADR
|
Dec 02, 2025 | BUY |
Strong Buy
+156.7% avg upside
10 analysts
|
$50.00
192.10% Upside
|
-35.2% |
|
JSPR
Jasper Therapeutics
|
Dec 02, 2025 | BUY |
Strong Buy
+6361.2% avg upside
17 analysts
|
$7.00
1445.34% Upside
|
-70.2% |
|
BCAB
BioAtla
|
Nov 14, 2025 | BUY |
Strong Buy
+2518.3% avg upside
13 analysts
|
$500.00
13579.79% Upside
|
-89.2% |
|
LYRA
Lyra Therapeutics
|
Nov 13, 2025 | HOLD |
Hold
+3282.4% avg upside
7 analysts
|
— | -80.4% |
|
VSTM
Verastem
|
Nov 04, 2025 | BUY |
Strong Buy
+260.2% avg upside
23 analysts
|
$20.00
385.46% Upside
|
-49.4% |
|
IDYA
IDEAYA Biosciences
|
Nov 04, 2025 | BUY |
Strong Buy
+55.2% avg upside
29 analysts
|
$62.00
98.58% Upside
|
+2.6% |
|
VKTX
Viking Therapeutics
|
Oct 30, 2025 | BUY |
Strong Buy
+141.1% avg upside
30 analysts
|
$125.00
311.41% Upside
|
-22.3% |
|
IPHA
Innate Pharma
|
Sep 17, 2025 | BUY |
Strong Buy
+261.8% avg upside
10 analysts
|
$8.00
341.94% Upside
|
-1.5% |
|
ELVN
Enliven Therapeutics
|
Aug 14, 2025 | BUY |
Strong Buy
+7.1% avg upside
14 analysts
|
$45.00
0.32% Downside
|
+119.8% |
|
LEGN
Legend Biotech
|
Aug 11, 2025 | BUY |
Strong Buy
+140.3% avg upside
27 analysts
|
$91.00
225.76% Upside
|
-1.0% |
|
IMCR
Immunocore Holdings
|
Mar 11, 2025 | BUY |
Strong Buy
+124.3% avg upside
22 analysts
|
$91.00
218.20% Upside
|
+14.4% |
|
CARM
Carisma Therapeutics
|
Jan 14, 2025 | HOLD |
Buy
+15294.7% avg upside
11 analysts
|
— | -90.8% |
|
ACET
Adicet Bio
|
Sep 10, 2024 | BUY |
Strong Buy
+212.8% avg upside
14 analysts
|
$6.00
25.84% Downside
|
-43.9% |
|
PROK
ProKidney
|
Sep 03, 2024 | BUY |
Buy
+260.7% avg upside
12 analysts
|
$5.00
173.17% Upside
|
-1.7% |
|
DTIL
Precision BioSciences
|
May 13, 2024 | BUY |
Strong Buy
+247.1% avg upside
12 analysts
|
$30.00
340.58% Upside
|
-55.3% |
|
MBIO
Mustang Bio
|
Mar 12, 2024 | BUY |
Strong Buy
+938.4% avg upside
5 analysts
|
$8.00
1130.74% Upside
|
-97.3% |
|
CASIF
CASI Pharmaceuticals
|
May 05, 2023 | HOLD |
Strong Buy
+14376.2% avg upside
5 analysts
|
— | · |
|
LITS
Lite Strategy
|
May 05, 2023 | HOLD |
Buy
+1215.4% avg upside
13 analysts
|
— | · |
|
SNGX
Soligenix
|
Dec 04, 2020 | BUY |
Buy
+726.0% avg upside
6 analysts
|
$4.00
901.32% Upside
|
-68.0% |
|
SCPX
Scorpius Holdings
|
Nov 11, 2020 | BUY |
Strong Buy
+1664672.8% avg upside
11 analysts
|
$28.00
2545354.59% Upside
|
· |
|
KRYS
Krystal Biotech
|
Nov 11, 2020 | BUY |
Strong Buy
-28.3% avg upside
19 analysts
|
$100.00
71.33% Downside
|
+17.7% |
|
ABEO
Abeona Therapeutics
|
Nov 11, 2020 | BUY |
Strong Buy
+195.8% avg upside
17 analysts
|
$3.00
47.93% Downside
|
-27.7% |
|
GERN
Geron
|
Nov 11, 2020 | BUY |
Strong Buy
+239.8% avg upside
19 analysts
|
$4.00
217.45% Upside
|
-20.3% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.